Insider Trading Alert - TJX, MKSI And JAZZ Traded By Insiders

Yesterday, May 26, 2016, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $0.02 to $20,083,643.73.

Highlighted Stocks Traded by Insiders:

TJX Companies (TJX) - FREE Research Report

Herrman Ernie, who is CEO & President at TJX Companies, sold 24,776 shares at $75.40 on May 26, 2016. Following this transaction, the CEO & President owned 444,661 shares meaning that the stake was reduced by 5.28% with the 24,776-share transaction.

The shares most recently traded at $76.41, up $1.01, or 1.32% since the insider transaction. Historical insider transactions for TJX Companies go as follows:

  • 4-Week # shares sold: 62,532
  • 12-Week # shares bought: 31,656
  • 12-Week # shares sold: 144,725
  • 24-Week # shares bought: 31,656
  • 24-Week # shares sold: 187,162

The average volume for TJX Companies has been 3.2 million shares per day over the past 30 days. TJX Companies has a market cap of $49.9 billion and is part of the services sector and retail industry. Shares are up 7.07% year-to-date as of the close of trading on Thursday.

The TJX Companies, Inc. operates as an off-price apparel and home fashions retailer in the United States and internationally. It operates through four segments: Marmaxx, HomeGoods, TJX Canada, and TJX International. The stock currently has a dividend yield of 1.38%. The company has a P/E ratio of 22.6. Currently, there are 15 analysts who rate TJX Companies a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TJX - FREE

TheStreet Quant Ratings rates TJX Companies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full TJX Companies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

MKS Instruments (MKSI) - FREE Research Report

Hanley Peter, who is Director at MKS Instruments, sold 500 shares at $39.00 on May 26, 2016. Following this transaction, the Director owned 7,292 shares meaning that the stake was reduced by 6.42% with the 500-share transaction.

The shares most recently traded at $40.57, up $1.57, or 3.88% since the insider transaction. Historical insider transactions for MKS Instruments go as follows:

  • 4-Week # shares bought: 3,500
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 3,500
  • 12-Week # shares sold: 15,000
  • 24-Week # shares bought: 3,500
  • 24-Week # shares sold: 17,500

The average volume for MKS Instruments has been 258,900 shares per day over the past 30 days. MKS Instruments has a market cap of $2.1 billion and is part of the technology sector and electronics industry. Shares are up 11.19% year-to-date as of the close of trading on Thursday.

MKS Instruments, Inc. provides instruments, subsystems, and process control solutions that measure, control, power, monitor, and analyze critical parameters of manufacturing processes in the United States and internationally. The stock currently has a dividend yield of 1.72%. The company has a P/E ratio of 19.7. Currently, there are 4 analysts who rate MKS Instruments a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MKSI - FREE

TheStreet Quant Ratings rates MKS Instruments as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full MKS Instruments Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Mulligan Seamus, who is Director at Jazz Pharmaceuticals, sold 27,968 shares at $150.29 on May 26, 2016. Following this transaction, the Director owned 1.1 million shares meaning that the stake was reduced by 2.54% with the 27,968-share transaction.

The shares most recently traded at $152.63, up $2.34, or 1.53% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 1,441
  • 12-Week # shares sold: 15,913
  • 24-Week # shares sold: 49,535

The average volume for Jazz Pharmaceuticals has been 770,500 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $9.2 billion and is part of the health care sector and drugs industry. Shares are up 8.69% year-to-date as of the close of trading on Thursday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 28.6. Currently, there are 13 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Goldman to Continue I-Bank Dominance; Netflix Bonds Draw Attention - ICYMI

Goldman to Continue I-Bank Dominance; Netflix Bonds Draw Attention - ICYMI

Texas Instruments CEO Resigns After Violating Code of Conduct

Texas Instruments CEO Resigns After Violating Code of Conduct

Video: Here's How Goldman Sachs May Change Under David Solomon

Video: Here's How Goldman Sachs May Change Under David Solomon

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony